Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors inside the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements analyze discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7,